| Literature DB >> 30879200 |
Eloísa Rubio-Beltrán1, Antoinette Maassen van den Brink2.
Abstract
Increasing knowledge about the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has led to the development of antibodies against this peptide or its receptor. However, CGRP is widely expressed throughout the body, participating not only in pathophysiological conditions but also in several physiological processes and homeostatic responses during pathophysiological events. Therefore, in this chapter, the risks of long-term blockade of the CGRP pathway will be discussed, with focus on the cardiovascular system, as this peptide has been described to have a protective role during ischemic events, and migraine patients present a higher risk of stroke and myocardial infarction.Entities:
Keywords: CGRP; CGRP (receptor) antibodies; Cardiovascular safety; Migraine; Myocardial infarction; Stroke
Mesh:
Substances:
Year: 2019 PMID: 30879200 DOI: 10.1007/164_2019_204
Source DB: PubMed Journal: Handb Exp Pharmacol ISSN: 0171-2004